Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CT-202 · 1 trial · 3 indications
Phase 1a will evaluate increasing doses of CT-202 based on the assessment of DLTs
ORR will be based on the overall response rate as assessed by Investigators according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Phase 1a | EXPERIMENTAL | Dose Escalation-Bayesian Optimal Interval (BOIN) Design with approximately 54 patients in dose escalation. |
| Phase 1b | EXPERIMENTAL | Phase 1b: Dose Expansion - participants will be evaluated in 4-6 cohorts at different doses and schedules of CT-202 |
| Name | Type | Description |
|---|---|---|
| CT-202 | DRUG | Nectin-4 bispecific |
Inclusion Criteria: * Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies * Participants with measurable disease per RECIST 1.1 * ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks * Participants have adequa...
CT-202 is an investigational small molecule developed by Context Therapeutics Inc. (ticker CNTX) for the treatment of triple negative breast cancer (TNBC). It is being studied in a first-time-in-human Phase 1a/1b clinical trial that also enrolls participants with colorectal and urothelial cancers. CT-202 has not been approved by the FDA and remains in clinical development.
CT-202 is being developed for triple negative breast cancer (TNBC), an aggressive form of breast cancer. The Phase 1a/1b trial of CT-202 enrolls participants with recurring TNBC, and also includes cohorts with colorectal cancer and urothelial cancer. CT-202 is investigational and has not been approved for any indication.
CT-202 targets Nectin-4, a protein expressed on tumor cells. CT-202 is described as a Nectin-4 directed bispecific antibody, meaning it is designed to bind Nectin-4 and engage a second target to drive an anti-tumor response. The Phase 1a/1b study is biomarker selected, enrolling participants whose tumors express the relevant biomarker.
CT-202 is being developed by Context Therapeutics Inc., which trades under the ticker CNTX. The company is running the first-time-in-human Phase 1a/1b study of CT-202 in participants with recurring triple negative breast, colorectal, and urothelial cancers. The trial is currently recruiting in Australia.
CT-202 is in Phase 1 development. The ongoing study is a Phase 1a/1b, first-time-in-human trial that is currently recruiting participants. CT-202 is investigational and has not received FDA approval. The trial has a planned enrollment of 162 participants and includes a controlled, randomized design.
CT-202 is being studied in one active clinical trial, NCT07545122, titled a Phase 1a/1b, first-time-in-human study of CT-202, a Nectin-4 directed bispecific antibody, in participants with recurring triple negative breast, colorectal, and urothelial cancers. The trial is recruiting, has a planned enrollment of 162 participants, and is conducted in Australia in adults 18 years and older.